A comprehensive analysis of publicly available data on PD-1/PD-L1 inhibitor monotherapy in PCa demonstrates that PD-1 inhibitors (pembrolizumab, nivolumab; n = 319) (118, 139, 141) were associated with frequent adverse events including gastrointestinal toxicities (nausea, diarrhea, decreased appetite), skin and subcutaneous tissue disorders (maculopapular rash, pruritus, rash), and systemic conditions (fatigue, asthenia, weight loss). Here, PDCD1 is linked to subcutaneous tissue disorder.